Blueprint Medicines Corp

Blueprint Medicines — Investor Presentation (January 2016)

19 slides from Blueprint Medicines's investor presentation, Jan 11, 2016

  1. Slide 1: This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act

    This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “

  2. Slide 2: Crafting Highly Selective Kinase Medicines for Patients With Genomically Defined Diseases

    Crafting Highly Selective Kinase Medicines for Patients With Genomically Defined Diseases >$17bn in small molecule kinase drug sales in 2014 Continued platform potential to generate new programs in 2016 and beyond Initial data potential by end of 2016 from 3 Phase 1 trials IND filing for BLU-667 (RE

  3. Slide 3: Poised to Build a Fully Integrated Business

    Poised to Build a Fully Integrated Business Potential for rapid clinical path in defined patient groups Multiple wholly-owned assets enabling a staged approach to potential commercialization in as little as 5 years Blueprint Medicines is Positioned to Build a Sustainable Business Prolific Discovery

  4. Slide 4: Led by a Team of Industry Innovators With Deep Expertise and Track Records of Success

    Led by a Team of Industry Innovators With Deep Expertise and Track Records of Success Christoph Lengauer, Ph.D. Chief Scientific Officer Jeff Albers Chief Executive Officer and President Andy Boral, M.D., Ph.D. Chief Medical Officer Prior Experience: Executive Management Raised $169M Gross in 2015 I

  5. Slide 5: Platform Integrates Innovative Target Discovery Engine and Proprietary Compound Library

    Platform Integrates Innovative Target Discovery Engine and Proprietary Compound Library to Yield Novel Drug Candidates Novel chemical matter Broad, diverse kinome coverage Annotated for rapid prosecution of medicinal chemistry Precisely tailored target product profiles Compound Library Proprietary g

  6. Slide 6: Diverse Portfolio With Clinical Stage Assets

    Initial Indications Stage of Development Commercial Rights BLU-285 (KIT Exon 17 Mutants and PDGFRα D842V Inhibitor) GIST Phase 1 Enrolling SM IND Accepted BLU-554 (FGFR4 Inhibitor) HCC Phase 1 Enrolling BLU-667 (RET Fusions & Resistant Mutants) NSCLC, thyroid Pre-clinical Rare Genetic Disease Target

  7. Slide 7: BLU-285 is a Selective and Potent Inhibitor of Exon Mutant KIT and D842V Mutant PDGFRα in GIST Models

    BLU-285 is a Selective and Potent Inhibitor of Exon 17 Mutant KIT and D842V Mutant PDGFRα in GIST Models Gastrointestinal Stromal Tumor Advanced GIST Details Patients* PDGFRα D842V 5-6% 500 Relapsed/ Refractory GIST 2L and beyond 12,000 1L GIST 1L 8,000 *GIST patient estimates represent incidence in

  8. Slide 8: BLU-285 is a Selective and Potent Inhibitor of D816V Mutant KIT in SM Models

    BLU-285 is a Selective and Potent Inhibitor of D816V Mutant KIT in SM Models Systemic Mastocytosis SM Subtypes Disease Burden Patients* Advanced SM >94% with KIT D816V mutation 4,500 Indolent SM 16,000 *SM patient estimates represent prevalence in these markets. Mast cell disorder Patients experienc

  9. Slide 9: BLU-285: Two Phase Clinical Studies Underway

    BLU-285: Two Phase 1 Clinical Studies Underway SM Expansion SM Dose Escalation Three groups of patients Aggressive SM Aggressive SM with another hematologic disorder Mast cell leukemia ~35 patients 2015 2017 GIST Expansion GIST Dose Escalation Two groups of patients KIT Exon 17 mutations PDGFRα D842

  10. Slide 10: BLU-554 is a Selective and Potent Inhibitor of FGFR4 in HCC Models

    Hepatocellular Carcinoma Advanced HCC Subsets Patients* 1L with FGFR4 activation 18,000 2L with FGFR4 activation 6,000 Liver cancer, most often HCC, is 2nd leading cause of cancer death worldwide Sorafenib only approved drug, no approved 2nd line therapy Up to 30% of HCC patients have abnormally act

  11. Slide 11: BLU-554: Phase 1 Clinical Study Underway

    Key Endpoints Primary Safety MTD Secondary Response rate Pharmacokinetics Alpha fetoprotein FGF19 in blood CYP7A1 RNA in tumor Patients selected for FGF19 expression by IHC ~25 HCC patients ~10 cholangiocarcinoma patients Expansion HCC Dose Escalation 3+3 design: ~25 patients Starting dose: 140 mg /

  12. Slide 12: BLU-667 is a Selective and Potent Inhibitor of RET in Non-Clinical Development

    Robust activity against wild-type RET as well as known and predicted resistance mutations Tumor regression in animal models driven by RET fusion proteins Initiate 28-day GLP toxicology 1H 2016 with IND filing anticipated by end of 2016 Approach Differentiated from Multi-kinase Inhibitors With RET Ac

  13. Slide 13: RET Program: Potent In Vivo Activity in RET and Predicted Resistance Mutants

    RET Program: Potent In Vivo Activity in RET and Predicted Resistance Mutants Vehicle 20mpk Reference QD 10mpk BLU6864 QD 30mpk BLU6864 QD 60mpk BLU6864 QD Ref BLU6864 Activity of BLU6864 (tool compound) in RET Fusion Allograft BLU6864 Ref Vehicle 20mpk Reference QD 10mpk BLU6864 QD 30mpk BLU6864 QD

  14. Slide 14: Alexion Collaboration Leverages Blueprint Platform in Rare Genetic Diseases

    Alexion Collaboration Leverages Blueprint Platform in Rare Genetic Diseases Collaboration Highlights Objective is to develop the first kinase inhibitor specifically designed for a rare and devastating genetic disease Blueprint Medicines is responsible for: Identification & optimization of drug candi

  15. Slide 15: Immunokinase Opportunity

    Immunokinase Opportunity Activation Tumor immunity (Replace or add on to checkpoint inhibitors) Inhibition Autoimmunity (MS, Lupus, RA) J Clin Invest. (2015) 125:1780-9. Kinases are critically involved in all aspects of immune system signaling

  16. Slide 16: Blueprint Medicines Achieved 2015 Goals

    Clinical Development BLU-285 GIST IND accepted; Phase I trial enrolling patients in dose escalation BLU-285 SM IND accepted; Phase 1 clinical sites opening BLU-554 HCC IND accepted; Phase I trial enrolling patients in dose escalation Received orphan drug designation for BLU-554 in HCC Discovery Sele

  17. Slide 17: Financial Overview

    Financial Overview* Market Cap ~$580M Shares Outstanding - Basic - Fully Diluted 27.1M 29.1M Outstanding Debt $7.9M Cash Position $179.8M Blueprint Medicines (BPMC): Entering 2016 in a Position of Financial Strength Ownership Summary* Existing cash balance expected to be sufficient to fund operation

  18. Slide 18: 2016 Goals: Advance 3 Trials to Clinical POC While Continuing to Progress Diversified Discovery Portfolio

    Clinical Development Report preliminary data from three ongoing trials BLU-285 in GIST BLU-285 in SM BLU-554 in HCC Finalize companion diagnostic development for BLU-285 and BLU-554 programs Discovery Advance RET BLU-667 to IND filing Disclose 6th discovery program Internally nominate 2 new discover

  19. Slide 19: 2016 Goals: Advance Trials to Clinical POC While Continuing to Progress Diversified Discovery Portfolio

    2016 Goals: Advance 3 Trials to Clinical POC While Sotueprint Continuing to Progress Diversified Discovery Portfolio eTEINE Clinical Development Discovery Corporate Report preliminary data from three ongoing trials - BLU-285 in GIST - BLU-285 in SM - BLU-554 in HCC Finalize companion diagnostic deve

Blueprint Medicines — Investor Presentation (January 2016) on 6ix